Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Recruiting
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: City of Hope Medical Center, Duarte, California +3 locations
Conditions: Smoldering Plasma Cell Myeloma
Tracking Results of Ablations to Combat AF Registry Generation 2
Recruiting
The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct concomitant open heart and/or hybrid ablation, and management of the Left Atrial Appendage concomitant to a cardiac ablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Loma Linda University Medical Center, Loma Linda, California +10 locations
Conditions: Atrial Fibrillation
Short Term Sirolimus Treatment and MRI of the Brain and Lungs
Recruiting
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure. Sirolimus is an FDA-approved medication which may improve the blood flow to the brain. Part I: This study is designed to see if sirolimus treatment improves MRI blood flow to the brain in individuals with and without a genetic predisposition to Alzheimer's disease. Part I of th... Read More
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
03/25/2025
Locations: University of Missouri-Columbia, Columbia, Missouri
Conditions: Genetic Predisposition to Disease, Healthy Volunteers
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Recruiting
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Recruiting
Ecological momentary interventions (EMI), which use phones to deliver messages to reduce alcohol use and related risk behaviors during or prior to drinking events, can help to address triggers in real-time. GPS tracking can determine when individuals visit places they have previously reported drinking or triggers to drink and then EMI messages can be delivered upon arrival to prevent risky alcohol use. A mobile app has been developed that uses GPS tracking to determine when individuals visit "ri... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut +1 locations
Conditions: Risk Behavior, Alcohol Use Disorder, HIV Infections
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Recruiting
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. The intent of E7 TCR-T cell treatment is to shrink or eliminate tumors and thereby facilitate definitive therapy and increase overall survival. This study seeks to determine 1) if E7 TCR-T cells can be administered without undue delay in definitive treatment, 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Investigating Novel Smoking Cessation Primary Care Interventions in Rural Environments
Recruiting
The purpose of this research study is to evaluate an electronic visit (e-visit) for smoking cessation across rural primary care settings. Participants will be randomly assigned to receive either the smoking cessation e-visit or not. The e-visit will look similar to an online questionnaire asking about smoking history, motivation to quit, and preferences for medications for quitting smoking. Participants may receive a prescription for a smoking cessation medication as an outcome of the e-visit, i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Smoking Cessation
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
Recruiting
The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/25/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Alcohol Use Disorder
Precision Dosing of Metformin in Youth With T2D
Recruiting
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
Gender:
ALL
Ages:
Between 10 years and 21 years
Trial Updated:
03/25/2025
Locations: UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic, Oakland, California +1 locations
Conditions: Type 2 Diabetes
Living Longer and Stronger With Spinal Cord Injury (SCI)
Recruiting
The purpose of this study is to develop a health promotion group intervention to meet the unique health promotion needs of people aging with SCI, to test the efficacy of the adapted intervention program, Living Longer and Stronger with SCI, in a randomized controlled trial and to assess the mechanisms through which the intervention may enhance physical, psychological, and social health.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: TIRR Memorial Hermann Spinal Cord Injury and Disability Research Center, Houston, Texas
Conditions: Spinal Cord Injuries
Assessing and Addressing Community Exposures to Environmental Contaminants
Recruiting
The purpose of this study is to build on our equitable, eight-year Tribal-academic partnership with the Ramapough Nation of northern NJ to advance tradition-centered farming practices and management strategies supporting sustainable food systems to relieve local food insecurity and nutritional deficiency, prevent disease and promote health. Furthermore, assessing the extent of environmental contamination, individual toxicant burdens and micronutrient levels and health disorders in Ramapough Trib... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2025
Locations: NYU Langone Health, New York, New York
Conditions: Environmental Exposure
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Recruiting
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Renal Cell Carcinoma